SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ADVR - Bulls no Bears
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: michael d kugler who wrote (355)4/21/1997 10:06:00 AM
From: Kingfisher   of 913
 
For sure there is risk in holding ADVR stock. But, the risk is no greater than holding many
many stocks - especially with the market being at such lofty levels. Is it not self evident
that the ADVR management carries a far greater risk than any shareholder if they are not
successful in getting Reticulose approved? To put it another way, both (a) existence and risk,
and (b) endeavor and risk, are synonymous.

Regardless of where the price of the stock will go, the important thing is that the
dispensing of Reticulose is approved by the FDA. If the FDA continues to keep Reticulose
[and possible new derivatives of this drug] off the shelves, the whole country and
world are at risk.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News